Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) generates a diverse stream of news centered on oncology, rare pediatric cancers, RNA-based therapeutics, AI-driven discovery, and nanomedicine. As a clinical-stage biopharmaceutical company, it regularly reports on scientific publications, joint venture progress, platform launches, and financing developments that shape its pipeline and corporate strategy.
Investors and researchers following OTLC news will encounter updates on key assets such as OT-101, a TGFB2 antisense agent associated with rare pediatric designation for DIPG through joint venture GMP Bio, and Sapu003, an intravenous Deciparticle formulation of everolimus developed by 45% owned JV Sapu Nano. Press releases highlight biomarker frameworks for identifying tumors likely to respond to Sapu003, pharmacokinetic data showing reduced gastrointestinal accumulation compared with oral everolimus, and broader Deciparticle platform data demonstrating formulation of multiple hydrophobic drug classes.
Oncotelic’s news flow also covers its PDAOAI evidence-interrogation platform, including open access for researchers to a TGF-β knowledge corpus of more than 125,000 PubMed abstracts via a dedicated Discord channel. Additional announcements describe peer-reviewed publications on context-dependent biomarkers in liver and pancreatic cancer, sub-15 nm nanoparticles for drug delivery, and survival-associated biological axes such as TGFB2, DNMT3A, and GMPS.
From a corporate and capital markets perspective, OTLC news includes independent valuations of its joint venture GMP Bio pipeline, potential fair-value remeasurements under U.S. GAAP, and registration statements related to equity purchase and note agreements with institutional investors. Regularly reviewing this news page allows readers to track how scientific advances, joint venture activities, AI platforms, and financing structures intersect within Oncotelic’s evolving oncology and rare disease portfolio.
Oncotelic Therapeutics (OTLC) and JV partner Sapu Bioscience published a review titled “Sub-15 nm Nanoparticles for Drug Delivery” in International Journal of Molecular Sciences on Nov 11, 2025.
The paper systematically examines nanoparticles sized 5–15 nm and highlights distinct advantages: deeper tumor penetration, reduced reticuloendothelial accumulation with rapid renal clearance, enhanced barrier diffusion including the blood–brain barrier, and quantum-scale surface properties enabling multifunctional imaging and therapy. The review links findings to Sapu’s Deciparticle™ platform and Sapu-003, an intravenous everolimus nanomedicine preparing for first-in-human evaluation.
Oncotelic Therapeutics (OTCQB: OTLC) was featured in an editorial published Oct 30, 2025 highlighting advances in nanomedicine for oncology drug delivery.
The piece frames industry trends toward precision drug‑delivery systems that aim to improve bioavailability, tumor targeting and therapeutic index while limiting toxicity. It notes growing regulator interest in nanocarrier technologies and positions Oncotelic's proprietary Deciparticle™ platform as a technology intended to enhance the bioavailability and therapeutic index of existing cancer drugs and to improve performance of underutilized compounds.
Oncotelic Therapeutics (OTLC) announced that Sapu Nano's investigational intravenous Deciparticle™ everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9–12, 2025, in San Antonio, TX. The company said the accepted abstracts cover clinical rationale, molecular biomarkers, and pharmacokinetic support for an ongoing Phase 1 trial of Sapu003 in HR+/HER2- metastatic breast cancer, renal cell carcinoma (RCC), and neuroendocrine tumors (NET).
The presentation session is scheduled for Thursday, December 11, 2025, 5:00 PM–6:30 PM CST and includes three abstracts focused on a RICTOR/RPTOR biomarker signature, formulation and manufacturing, and pharmacokinetic rationale for IV everolimus.
Oncotelic Therapeutics (OTCQB: OTLC) on Oct 28, 2025 highlighted nanomedicine editorial placement and clinical progress for its Deciparticle(TM) drug‑delivery platform.
The company noted placement in a NetworkNewsWire editorial and said its intravenous Deciparticle formulation of everolimus, Sapu‑003, has advanced into human trials, positioning the platform to potentially increase bioavailability and therapeutic index of underperforming oncology drugs.
Oncotelic (OTLC) announced three accepted abstracts for the 2025 San Antonio Breast Cancer Symposium (SABCS), Dec 9–12, 2025, with presentations on Deciparticle™ everolimus (Sapu003).
The presentations (Thursday, Dec 11, 2025 | 5:00 PM–6:30 PM CST) cover: a RICTOR/ RPTOR gene-expression signature as a predictive biomarker, clinic-ready manufacturing of the Deciparticle formulation, and the pharmacokinetic rationale supporting an ongoing Phase 1 trial in HR+/HER2- metastatic breast cancer. Studies were conducted with SOCRU, Ingenu CRO, and Medicilon and emphasize translational biomarker work, PK modeling, and scalable GMP manufacturing for intravenous everolimus.
Oncotelic (OTLC) will present at the LD Micro Main Event XIX on Tuesday, October 21, 2025 at 11:30 a.m. PT at the Hotel del Coronado in San Diego.
CEO Vuong Trieu, Ph.D., will give the presentation and outline progress on the company’s lead program Sapu, a 45%‑owned joint venture, highlighting formulation optimization, regulatory engagement, and advancement toward a clinical trial.
The three‑day conference runs Oct 19–21, 2025, features about 120 companies, half‑hour presentations, and one‑on‑one investor meetings.
Sapu Nano (OTLC) announced that Sapu-003, the company's first intravenous Deciparticle™ formulation of everolimus, has entered a Phase 1 study in Australia and was presented at the 8th Australian Translational Breast Cancer Research Symposium on October 8, 2025. The trial (ACTRN12625001083482) is open for enrollment at leading Australian oncology centres for adults with advanced HR+/HER2– breast cancer and other mTOR-sensitive tumors who have exhausted standard therapies. The program is partnered with SOCRU, Ingenū, and Medicilon to support clinical execution, regulatory alignment, and product supply.
Sapu Nano, part of a joint venture involving Oncotelic Therapeutics (OTCQB: OTLC), has received approval from Australia's HREC to begin Phase 1 human clinical trials for Sapu003, an injectable form of Everolimus for breast cancer treatment.
The key innovation lies in Sapu003's delivery method: While the FDA-approved oral version (Afinitor®) has only 10% bioavailability, Sapu003 uses proprietary Deciparticle™ technology for intravenous delivery, enabling 100% drug absorption. This breakthrough could potentially improve efficacy in treating breast cancer, kidney cancer, and certain rare tumors.
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotechnology sector, focusing on developing treatments for cancer and rare diseases. Under the leadership of CEO Dr. Vuong Trieu, the company is leveraging artificial intelligence and nanomedicine to innovate in biotechnology.
The company's intellectual property portfolio includes approximately 500 patent applications and 75 granted patents. Oncotelic is specifically targeting difficult-to-treat cancers such as glioblastoma and pancreatic cancer, along with rare pediatric disorders, addressing significant unmet medical needs in these areas.
Oncotelic Therapeutics (OTCQB: OTLC) is positioning itself as a key player in the biotech industry, focusing on developing treatments for aggressive cancers and pediatric rare diseases. Under CEO Dr. Vuong Trieu's leadership, the company is leveraging artificial intelligence, nanomedicine, and novel clinical models to advance its therapeutic pipeline.
The company's intellectual property portfolio includes over 500 patent applications and 75 issued patents. Oncotelic is specifically targeting difficult-to-treat conditions such as glioblastoma and pancreatic cancer, aiming to address significant unmet medical needs in these areas through RNA-based and immunotherapy approaches.